Efficacy and safety of first-line immunotherapy-related induction and maintenance therapy for extensive-stage small cell lung cancer: a systematic review and Bayesian network meta-analysis. (PubMed, Front Pharmacol) - Oct 1, 2026 - "The atezolizumab + lurbinectedin + chemotherapy and benmelstobart + anlotinib + chemotherapy regimens showed the greatest potential for superior PFS and OS compared with chemotherapy alone...The nivolumab + ipilimumab regimen was associated with the highest risk of severe toxicity...This study provides valuable insights into therapeutic drug selection for ES-SCLC. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261402898, identifier 420261402898."
Journal • Retrospective data • Review • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
|
|
Dong-Sheng Zhang; Hong-Jing Yu; Jun-Chen Liu; Qi Deng; Zhi Chen
|